Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/4282486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567935254659072 |
|---|---|
| author | Jennifer L. Miatech John H. Hughes Dillon K. McCarty M. Patrick Stagg |
| author_facet | Jennifer L. Miatech John H. Hughes Dillon K. McCarty M. Patrick Stagg |
| author_sort | Jennifer L. Miatech |
| collection | DOAJ |
| description | Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibrutinib is thought to be related to its effect on several platelet signaling pathways, which can be exacerbated in the setting of concurrent antiplatelet or anticoagulant therapy. We present an 82-year-old male with CLL on ibrutinib and concurrent antiplatelet therapy who developed cardiac tamponade due to a hemorrhagic pericardial effusion requiring emergent placement of a pericardial window. This case further highlights the risk of major bleeding in patients treated with ibrutinib and concurrent antiplatelet therapy. |
| format | Article |
| id | doaj-art-501aed1704af431d9d7f4352b1599d1e |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-501aed1704af431d9d7f4352b1599d1e2025-02-03T01:00:05ZengWileyCase Reports in Hematology2090-65602090-65792020-01-01202010.1155/2020/42824864282486Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet TherapyJennifer L. Miatech0John H. Hughes1Dillon K. McCarty2M. Patrick Stagg3Baton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USABaton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USABaton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USABaton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USAIbrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibrutinib is thought to be related to its effect on several platelet signaling pathways, which can be exacerbated in the setting of concurrent antiplatelet or anticoagulant therapy. We present an 82-year-old male with CLL on ibrutinib and concurrent antiplatelet therapy who developed cardiac tamponade due to a hemorrhagic pericardial effusion requiring emergent placement of a pericardial window. This case further highlights the risk of major bleeding in patients treated with ibrutinib and concurrent antiplatelet therapy.http://dx.doi.org/10.1155/2020/4282486 |
| spellingShingle | Jennifer L. Miatech John H. Hughes Dillon K. McCarty M. Patrick Stagg Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy Case Reports in Hematology |
| title | Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy |
| title_full | Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy |
| title_fullStr | Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy |
| title_full_unstemmed | Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy |
| title_short | Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy |
| title_sort | ibrutinib associated cardiac tamponade with concurrent antiplatelet therapy |
| url | http://dx.doi.org/10.1155/2020/4282486 |
| work_keys_str_mv | AT jenniferlmiatech ibrutinibassociatedcardiactamponadewithconcurrentantiplatelettherapy AT johnhhughes ibrutinibassociatedcardiactamponadewithconcurrentantiplatelettherapy AT dillonkmccarty ibrutinibassociatedcardiactamponadewithconcurrentantiplatelettherapy AT mpatrickstagg ibrutinibassociatedcardiactamponadewithconcurrentantiplatelettherapy |